Harbor Capital Advisors, Inc. Exelixis, Inc. Transaction History
Harbor Capital Advisors, Inc.
- $1.29 Billion
- Q3 2025
A detailed history of Harbor Capital Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 657 shares of EXEL stock, worth $27,364. This represents 0.0% of its overall portfolio holdings.
Number of Shares
657
Previous 1,853
64.54%
Holding current value
$27,364
Previous $82,000
67.07%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
695Shares Held
257MCall Options Held
1.5MPut Options Held
1.71M-
Black Rock Inc. New York, NY33.5MShares$1.4 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA26.1MShares$1.09 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA19.5MShares$812 Million3.48% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.5MShares$644 Million0.9% of portfolio
-
State Street Corp Boston, MA11.1MShares$463 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.4B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...